EGFR and non-small cell lung carcinoma: While afatinib achieves superior efficacy in progression-free survival (PFS) and overall survival (OS) compared with conventional chemotherapy in NSCLC, progression inevitably occurs after EGFR TKI treatment for acquired resistance, which presents challenges in the treatment of NSCLC (7, 8).